Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Mitochondria Stumble Their Way Along Axons in ALS Model
6 January 2012. People with amyotrophic lateral sclerosis struggle to move, and it appears some of their organelles have the same problem. Mitochondria normally sashay up and down neuronal axons, arriving fresh at the synapse and smartly returning to the cell body to be recycled. But in ALS, these organelles flounder in their travels as well as in their ability to provide the energy that neurons crave, according to new research. In the January 4 Journal of Neuroscience, researchers from the Weill Medical College of Cornell University in New York City report that in a neuron model for ALS, mitochondria exhibit a variety of defects, including lackadaisical fusion and a lollygagging passage from axon tips to the cell body.

Mitochondrial defects are associated with Alzheimer’s, Parkinson’s (see ARF related news story), and Huntington’s diseases (see ARF related news story). “This study adds ALS as one of the neurodegenerative diseases where mitochondrial dynamics is clearly affected and most likely playing a role in neurodegeneration,” said study senior author Giovanni Manfredi, who led the work with first author Jordi Magrané. Their and others’ work previously indicated a role for mitochondria (reviewed in Magrané and Manfredi, 2009) and axonal transport (De Vos et al., 2007; see ARF related news story and ARF news story) in degeneration of motor neurons in ALS, but “this is clearly the best and most comprehensive study on this topic as yet,” commented Flint Beal, who is also at Weill Medical College but was not involved in the publication.

To label mitochondria and follow their comings and goings, Magrané hooked the mitochondrial-targeting pre-sequence from cytochrome c oxidase to a photo-switchable fluorescent protein called Dendra. Dendra starts out green, but when photoactivated by blue-green light converts irreversibly to red. Magrané transfected this mitoDendra into primary embryonic motor neurons. The cells came from rats expressing human SOD1 with the G93A mutation that causes an inherited form of ALS. As controls, Magrané used rats expressing wild-type human SOD1 as well as non-transgenic animals.

To examine mitochondrial fusion, the researchers photo-converted some of the mitoDendra in each cell soma to red. Then, as green- and red-labeled mitochondria mixed, yellow mitochondria appeared, signifying fusion of organelles. In motor neurons from non-transgenic rats, it took approximately 40 minutes for yellow signals to appear. This process took more than twice as long in mSOD1 cells. Similarly, in the axons of the mSOD1 neurons, the scientists observed that mitochondria—specifically those moving in the retrograde direction—fused with each other approximately half as often as they did in control axons.

The researchers then examined mitochondrial transport along axons. In control neurons, the organelles traveled in the anterograde direction at approximately 0.2 microns per second and retrogradely at about 0.3 microns per second. While anterograde transport proceeded at normal velocity in mSOD1 cells, mitochondria coming back up in the retrograde direction traveled more slowly and paused more often than in control axons. They averaged only 0.2 microns per second. Since retrograde-moving mitochondria are destined to be recycled into fresh new organelles in the cell body, this leisurely pace could impact the production of reinvigorated mitochondria, Manfredi suggested.

Altered transport and fusion could alter the size of mitochondria, so Magrané measured the length of the organelles in axons as the cells aged. Mitochondria were shorter in the mSOD1 neurons, and the defect appeared to start at the axon tips and work toward the cell body. At five days in culture, control cells possessed mitochondria of approximately three microns in length in both proximal and distal areas. In the mSOD1 axons, the proximal mitochondria remained normal size, but the distal ones were only two microns long. After 10 days in culture, proximal mitochondria stretched to four microns in non-transgenic neurons, but only 3.3 microns in mSOD1 neuronal cultures.

This distal-first sequence of events in culture mirrors the progression of ALS pathology, in which atrophy appears to begin at the neuromuscular junction and progress to the cell body in a “dying back” of the axon (Fischer et al., 2004), noted Xiongwei Zhu and Xinglong Wang, of Case Western Reserve University in Cleveland, Ohio, in an e-mail to ARF. The data “support a critical role of mitochondria dysfunction in the dying back mechanism of the SOD1-familial ALS model,” wrote Zhu and Wang, who were not involved in the current study.

Manfredi and Magrané wondered if all retrograde transport would be affected, or only that of mitochondria. To find out, they used Dendra to label membrane-bound organelles (MBOs), vesicles that also shuttle up and down axons. MBO transit was unaffected by mSOD1, suggesting the axon’s rails and engines must be intact. Mitochondrial-trafficking deficiency also only appeared in motor neurons, Magrané found. When he examined mitochondrial dynamics in primary cortical neurons, transport was normal in the mSOD1-expressing cells.

The researchers do not yet know how mSOD1 alters mitochondrial transport. It might interrupt the organelles’ interactions with microtubules or molecular motors, Manfredi speculated (Ström et al., 2008). While mSOD1 is found all over the cell, he and Magrané have previously shown that when the mutant protein is targeted solely to mitochondria, it recapitulates many features of ALS (see ARF related news story on Igoudjil et al., 2011; Magrané et al., 2009). Therefore, it is possible that some intrinsic deficiency in mSOD1-toting mitochondria affects their morphology and transport.

“I think this work will solidify the concept that impairment of mitochondrial dynamics in axons can be a significant contributing factor to ALS etiology,” said Haining Zhu of the University of Kentucky in Lexington, who was not involved in the study. And mutant SOD1 is likely not the only way to muck up mitochondrial transport. Other rodent models for ALS, based on mutations in genes such as TDP-43, also exhibit abnormal mitochondrial morphology (see ARF related news story on Xu et al., 2010). Those genetic mutations, however, account for only a small percentage of human ALS. Most cases are sporadic, and mitochondrial transport might turn out to be amiss in those motor neurons, too, Beal suggested. “I think it is feasible that it is going to be a generalized problem,” he said.

Moreover, mitochondrial defects are emerging as a common thread among neurodegenerative disease. “Neurons are energy-demanding,” Haining Zhu noted, suggesting, “you may have different insults in different diseases, but they all could lead to mitochondrial abnormality.”—Amber Dance.

Reference:
Magrané J, Sahawneh MA, Przedborski S, Estévez AG, Manfredi G. Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J Neurosci. 2012 Jan 4;32(1):229-42. Abstract

 
Comments on News and Primary Papers
  Comment by:  Allen Roses (Disclosure)
Submitted 9 January 2012  |  Permalink Posted 9 January 2012
  I recommend the Primary Papers

  Primary Papers: Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons.

Comment by:  Xinglong Wang, Xiongwei Zhu
Submitted 9 January 2012  |  Permalink Posted 9 January 2012

This is a very well-executed study with very careful and detailed measurement of mitochondrial morphology and transport in motor neurons in an ALS model, and which extends the authors’ previous findings (Magrané et al., 2009). Mitochondrial Dendra is a very useful tool, but this is not the novelty here, since the same mitoDendra is already widely used by many groups. In this study, the authors convincingly demonstrated that mutant SOD1 impaired mitochondrial fusion and retrograde transport of mitochondria only in motor neurons. Of more pathogenic significance is that they found mitochondrial fragmentation progresses from distal to proximal segments over time (at five days in vitro, only distal segments demonstrated fragmented mitochondria, while at DIV10, both distal and proximal mitochondria fragment). That anterograde-moving mitochondria in mutant SOD1 motor neurons have lower mitochondrial membrane potential than those in controls supports a critical role of mitochondria dysfunction in the dying back mechanism of the SOD1-FALS model. They also confirmed the correlation between...  Read more

  Comment by:  Vincent Tedone
Submitted 9 January 2012  |  Permalink Posted 11 January 2012
  I recommend the Primary Papers
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad